Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
|||
| Line 27: | Line 27: | ||
[[Category:EMA approved drugs]] | [[Category:EMA approved drugs]] | ||
| + | [[Category:FDA approved in 2021]] | ||
Revision as of 01:59, 28 December 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established (work in progress)
Patient drug information
History of changes in FDA indication
- 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
Also known as
- Code name: AV-951
- Brand name: Fotivda